Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07307612 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

High-energy Human Milk Diets in the First Two Weeks After Birth to Reduce BPD in Extremely Preterm Infants

Study acronym: MEND-BPD
StatusRecruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Recruitment opened Start date changed from estimate of Aug 15, 2026 to Sep 21, 2026 · Site details revised · Eligibility criteria expanded, about 5 words Show 3 more changesShow less
    • Start date changed from estimate of Aug 15, 2026 to Sep 21, 2026
    • Site details revised
    • Eligibility criteria expanded, about 5 words
  2. Start date: May 31, 2026 to Aug 15, 2026v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This Phase II, parallel-group, masked, randomized clinical trial aims to evaluate whether a DHA/ARA-enriched, fortified human milk diet administered during the first 14 days of life reduces respiratory morbidity and improves lung function in extremely preterm (EPT) infants (born at ≤28 weeks gestation).
Trial Details
NCT Number NCT07307612
Lead Sponsor University of Alabama at Birmingham
Collaborators: National Heart, Lung, and Blood Institute (NHLBI)
Conditions Extreme Prematurity, Enteral Nutrition, Bronchopulmonary Dysplasia
Enrollment 150 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov